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Abstract: Irritable bowel syndrome (IBS) causes gastrointestinal symptoms such as abdominal 
pain, bloating, and bowel pattern abnormalities, which compromise patients’ daily functioning. 
Common therapies address one or two IBS symptoms, while others offer wider symptom control, 
presumably by targeting pathophysiologic mechanisms of IBS. The aim of this targeted literature 
review was to capture clinical trial reports of agents receiving the highest recommendation 
(Grade 1) for treatment of IBS from the 2009 American College of Gastroenterology IBS 
Task Force, with an emphasis on diarrhea-predominant IBS. Literature searches in PubMed 
captured articles detailing randomized placebo-controlled trials in IBS/diarrhea-predominant 
IBS for agents receiving Grade I (strong) 2009 American College of Gastroenterology IBS 
Task Force recommendations: tricyclic antidepressants, nonabsorbable antibiotics, and the 
5-HT3 receptor antagonist alosetron. Studies specific for constipation-predominant IBS were 
excluded. Tricyclic antidepressants appear to improve global IBS symptoms but have variable 
effects on abdominal pain and uncertain tolerability; effects on stool consistency, frequency, 
and urgency were not adequately assessed. Nonabsorbable antibiotics show positive effects on 
global symptoms, abdominal pain, bloating, and stool consistency but may be most efficacious 
in patients with altered intestinal microbiota. Alosetron improves global symptoms and 
abdominal pain and normalizes bowel irregularities, including stool frequency, consistency, 
and fecal urgency. Both the nonabsorbable antibiotic rifaximin and the 5-HT3 receptor 
antagonist alosetron improve quality of life. Targeted therapies provide more complete relief 
of IBS symptoms than conventional agents. Familiarization with the quantity and quality of 
evidence of effectiveness can facilitate more individualized treatment plans for patients with 
this heterogeneous disorder.
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Introduction
Irritable bowel syndrome (IBS) is a chronic functional gastrointestinal (GI) disorder 
characterized by episodes of abdominal pain and/or discomfort and altered bowel 
  habits. A previous systematic review of the literature showed that the prevalence of IBS 
ranged from 3% to 20% in North America, with most estimates falling between 10% 
and 15%.1 A more recent community-based survey supports these earlier estimates, 
finding a prevalence of IBS in the US of approximately 14.1%.2 More than 80% of the 
surveyed patients were 18–54 years of age, and 64% were women. Further, among US 
patients with symptoms of IBS, more than three-quarters had not received a definitive 
diagnosis.2 IBS diagnoses are now often classified according to three symptom patterns: 
diarrhea-predominant IBS (IBS-D), constipation-predominant IBS (IBS-C), and an 
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alternating pattern of these two (IBS-A). The true prevalence 
of each IBS subtype is not established, but IBS-A and IBS-D 
are thought to be more common.2–4
The negative impact of IBS symptoms on daily function-
ing and quality of life can be substantial. The IBS in the Real 
World Survey,5 conducted by the International Foundation 
of Functional Gastrointestinal Disorders, found that nearly 
half of patients diagnosed with IBS experience daily symp-
toms. Among survey respondents, 26% reported missing at 
least 1 day of work or school during the preceding 3 months 
(average 7.9 days), and 68% reported missing at least 1 day 
of personal activities (average 10.5 days) because of their ill-
ness.5 Nearly 90% of patients with IBS-D report experiencing 
abdominal pain, gas, and sudden urgency5 and, as symptom 
severity increases, so too does the level of impairment in 
daily functioning and quality of life. Patients with severe IBS 
symptoms may experience quality of life impairments that 
are comparable with, or even greater than, those associated 
with diabetes or depression.6,7
In 2009, the American College of Gastroenterology 
(ACG) IBS Task Force updated its evidence-based posi-
tion statement on the management of IBS.3 In the update,   
the Task Force determined that the strongest evidence for 
efficacy in IBS-D existed for three classes of medications: 
tricyclic antidepressants (TCAs), antibiotics (ie, rifaximin), 
and the 5-HT3 antagonist alosetron.3 Each class received a 
strong recommendation for clinical use in IBS (Grade 1B), 
indicating that the evidence is of moderate to high quality 
and that the benefits clearly outweigh any risk or burden 
of therapy.3 To provide further detail regarding the ACG 
recommendations, a comprehensive search of the literature 
was carried out for published clinical studies involving these 
agents in the treatment of IBS, with special attention to the 
IBS-D subtype, with a goal of highlighting the underlying 
pathophysiologic mechanisms and delineating the breadth 
of their respective treatment effects.
Methods
A literature search using PubMed was conducted for random-
ized placebo-controlled trials in IBS reported in English over 
the past 25 years and used the search terms “irritable bowel 
syndrome,” “colonic diseases,” “functional disease,” “IBS,” 
“spastic colon,” and/or “irritable colon.” Trials evaluating IBS-
C, those conducted in children, clinical case studies, open-label 
studies, and studies with an active comparator alone (ie, studies 
with no placebo arm) were excluded. Articles that evaluated 
TCAs, antibiotics, or alosetron in IBS were included for this 
review. To capture any other r  elevant clinical trials meeting 
our inclusion criteria that had not been published in full, 
similar searches were carried out to find congress abstracts in 
EMBASE, Biosis, Inside Conferences on Dialog, and Confer-
ence Papers Index from the past 5 years; relevant information 
from these searches was included.
Results
Pathophysiology
The pathophysiology of IBS is traditionally linked to a 
complex interaction between altered gut motility, visceral 
hypersensitivity, and environmental stress. Although IBS-D 
is generally thought to be associated with increased motility 
patterns and IBS-C with decreased motility, no consensus 
definition exists on the pattern of motility responsible for 
either bowel pattern abnormality.8 The key role of   serotonin 
in intestinal motor and secretory function has given rise 
to the hypothesis that altered serotonin signaling leads 
to either   constipation or diarrhea in IBS.9,10 Specifically, 
increased serotonin activity may be associated with IBS-D, 
and decreased serotonin activity may be associated with 
IBS-C.11,12 In   addition to these well-recognized abnormalities, 
a dysfunctional brain-gut axis involving the central, auto-
nomic, and enteric nervous systems has also been implicated 
in IBS pathophysiology. Other theories proposed in IBS 
include various causes such as inflammation, disturbances in 
immune function, and alterations in the gut microbiota.13–15
Conventional therapies
The management of IBS often includes the use of conventional 
therapies, which are those that are directed toward specific 
symptoms of IBS (eg, loperamide for diarrhea, laxatives for 
constipation, antispasmodics for abdominal pain).15,16 Because 
of the heterogeneous nature of their symptoms, patients with 
IBS are often treated with medications from more than one drug 
class in an effort to achieve relief. However, use of multiple 
conventional therapies has not provided sufficient benefit, and 
IBS patients have expressed dissatisfaction with these treat-
ment regimens. In the IBS in the Real World Survey,5 40% of 
respondents rated their over-the-counter drug as “not effective” 
in relieving IBS symptoms. Few controlled trials have demon-
strated efficacy for these conventional agents in IBS, despite 
their frequent use. Furthermore, greater drug exposure from use 
of multiple therapies may lead to higher safety risks.
Targeted therapies
In contrast with conventional therapies, which treat only 
one specific symptom of IBS, targeted treatment strategies 
are directed at addressing the underlying pathophysiologic 
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mechanisms that are believed to cause IBS. These targeted 
treatments have the potential to relieve multiple rather than 
single symptoms of IBS. For example, the TCA imipramine 
has been shown to prolong both orocecal and whole gut transit 
times in patients with IBS-D,17 which is likely the result of 
its cholinergic and histaminergic antagonism. Additionally, 
inhibition of the reuptake of norepinephrine and/or serotonin 
(depending on the TCA) both centrally and peripherally 
can reduce nociception.9,10,18,19 In view of the controversial 
hypothesis that small intestinal bacterial overgrowth (SIBO) 
may play a role in the pathogenesis of IBS,20 nonabsorbable 
antibiotics have been investigated for the treatment of IBS,21,22 
where benefits are presumably due to effects on gut microflora. 
Alosetron, a selective 5-HT3 antagonist, has also been shown to 
provide multisymptom relief in IBS. 5-HT3 receptors are exten-
sively distributed on enteric neurons in the human GI tract. 
A  ntagonism by alosetron at 5-HT3 receptors leads to reduction 
in visceral pain,23 slowed colonic transit,24 and decreased GI 
secretions,25 actions that address the underlying pathophysi-
ological mechanisms that are operant in IBS. Of these agents, 
alosetron is currently the only Food and Drug Administration 
(FDA)-approved agent for the treatment of women with severe 
IBS-D.26 In this article we review the current evidence for each 
of these agents as it pertains to IBS-D.
Antidepressants
In its updated position statement, the ACG IBS Task Force 
asserted that TCAs are more effective than placebo at reliev-
ing global IBS symptoms, noting that these agents also 
appear to reduce abdominal pain.3 A recent meta-analysis 
including 579 IBS patients treated with TCAs across nine 
studies showed short-term (#12 weeks) benefits.27 In this 
review, symptoms of IBS were less likely to persist with 
TCA therapy than with placebo (relative risk 0.68; 95% 
confidence interval [CI] 0.56–0.83); the number needed to 
treat to prevent IBS symptoms from persisting in one patient 
was four (95% CI 3–8).27 Unfortunately, no long-term studies 
have evaluated the use of TCAs in the treatment of IBS, and 
therefore the efficacy (and safety) of extended treatment with 
TCAs remains uncertain.3
TCAs may be effective in IBS, particularly in IBS-D, by 
both central and peripheral mechanisms that include increas-
ing pain thresholds, altering visceral sensation, relieving 
concomitant depression, and altering gut transit times.3,27 
The anticholinergic effects of the TCAs and their ability to 
prolong intestinal transit times are the reasons these agents 
are preferred over the selective serotonin-reuptake inhibitors 
(SSRIs) in IBS-D.3,17,27
Although TCAs were first used in the treatment of func-
tional bowel disorders more than 30 years ago,16 only a limited 
number of controlled trials have evaluated their efficacy in 
IBS, and even fewer have been carried out in patients with 
IBS-D (Table 1).28–33 Amitriptyline,28,29 desipramine,30,31 and 
imipramine32,33 have each been evaluated in two randomized 
controlled trials in patients with IBS. Four of these trials were 
small, including 51 or fewer patients,28–30,33 one included 
107 patients,32 and the largest TCA trial to date included 
431 patients, who were divided into two treatment groups: 
pharmacotherapy and psychoeducation.31 In five of the six 
trials, IBS was diagnosed using Rome I28,31 or Rome II29,32,33 
diagnostic criteria, while in one, the diagnosis was made by a 
comprehensive history and physical exam with laboratory and 
imaging studies ruling out organic disease.30 Only one trial 
limited enrollment specifically to IBS-D patients,29 and of the 
two trials that characterized randomized patients by predomi-
nant bowel disturbance (ie, diarrhea or constipation),30,33 only 
one reported treatment results by IBS subtype.30
Amitriptyline
Rajagopalan et al28 evaluated the effects of amitriptyline (25–
75 mg at bedtime) compared with placebo over 12 weeks in 
40 adults with IBS. Amitriptyline was significantly superior to 
placebo in terms of the percentage of patients showing global 
improvement (63.6% vs 25.9%; P , 0.01), number of days per 
week with abdominal pain (1.45 days vs 4.00 days; P , 0.01), 
number of days per week that patients felt well (5.18 days 
vs 1.91 days; P , 0.001), and number of days per week 
with satisfactory bowel movements (5.27 days vs 3.09 days; 
P , 0.05). In a study limited to IBS-D patients (N = 50), 
Vahedi et al29 reported that amitriptyline 10 mg given every 
night for 2 months produced significant improvement in IBS 
symptoms (P = 0.005), reduction in the frequency of patients 
with loose stools each day (12% vs 28%; P , 0.05), and a 
higher percentage of patients with a complete response (63% 
vs 26%; P = 0.01) compared with placebo. Abdominal pain 
relief did not differ between the two treatment groups.
imipramine
In an evaluation of 51 patients with IBS, 73% of whom had 
IBS-D, Talley et al33 compared the effects of imipramine 
(25–50 mg/d) and citalopram (20–40 mg/d) with those of 
placebo over 12 weeks of treatment. Neither active treatment 
was superior to placebo on the primary outcome of adequate 
relief of IBS symptoms. Likewise, abdominal pain scores 
did not significantly differ between the active treatment 
and placebo groups. However, imipramine was associated 
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with significant reductions in the Bowel Symptom Severity 
 Rating Scale scores for both disability (P = 0.03) and distress 
(P = 0.05) compared with placebo. More patients receiving 
imipramine than citalopram or placebo reported side effects, 
but these differences were not significant.33 In a second 
study, reported by Abdul-Baki et al,32 107 female patients 
with IBS who had failed antispasmodics were randomized 
to receive imipramine (25–50 mg at bedtime) or placebo. 
Patient-reported global symptom relief, the primary outcome 
measure, did not differ significantly between those patients 
treated with imipramine and those treated with placebo 
(42.4% vs 25.0%; P = 0.06).32
Desipramine
In a double-blind crossover study comparing desipramine, 
atropine, and placebo, Greenbaum et al30 examined 28 
patients with IBS (nine constipation-predominant and 19 
diarrhea-predominant by self-report) and found that the 
mean pain index score decreased during all test periods, 
with desipramine providing statistically significant pain 
reduction compared with both atropine (P , 0.025) and 
placebo (P , 0.0025). The improvement found in patients 
with diarrhea predominance accounted for these differences 
(P , 0.01). Of the 15 desipramine-treated patients reporting 
global improvement while taking desipramine, 87% (n = 13) 
had diarrhea predominance.30
In the largest trial evaluating a TCA, Drossman et al31 
compared desipramine and placebo in a subset of 431 patients 
with functional bowel disorders, more than 80% of whom had 
IBS. Patients were randomized to receive pharmacotherapy 
(n = 216) with either desipramine (50–150 mg/d) or placebo 
for 12 weeks or psychoeducation (n = 215) with either twelve 
1-hour sessions of cognitive behavioral therapy or twelve edu-
cational sessions for review of symptom diaries and educational 
material on functional bowel disorders. Using a composite end-
point consisting of four ratings (treatment satisfaction, global 
well-being, pain on the McGill Pain Questionnaire, and quality 
of life on the IBS Quality of Life Questionnaire) as the primary 
outcome measure, investigators found no significant difference 
between desipramine and placebo in the intent-to-treat popula-
tion; however, desipramine was statistically superior to placebo 
in the per-protocol assessment, consisting of all patients who 
completed at least eight visits during the study (desipramine 
n = 97, placebo n = 56; P = 0.03).31
Adverse events in iBS patients treated with TCAs
Adverse events of dizziness, drowsiness, constipation, 
and dry mouth occurred with greater frequency during 
TCA treatment compared with placebo.30–33 In the trial by 
  Drossman et al,31 adverse effects were cited as the primary 
reason for dropout (n = 26, 19.3%) in the desipramine 
group compared with those receiving placebo (n = 3, 
5.5%). Although anticholinergic effects often develop with 
increasing TCA dosages,16 the secondary amines (eg, desip-
ramine, nortriptyline) are generally better tolerated than 
the tertiary amines (eg, amitriptyline, imipramine) because 
of their lower affinity for cholinergic, histaminergic, and 
α-adrenergic receptors.16 Other safety concerns with TCAs 
include the risk of cardiac arrhythmias and the potential for 
fatal overdose, which is of particular concern in IBS patients 
because of a higher prevalence of suicidal ideation in this 
population.16,34
Selective serotonin-reuptake inhibitors
Five small randomized placebo-controlled studies assessed 
the capacity of SSRIs to improve IBS symptoms.33,35–38 
  Relevant studies are summarized in Table 2. Only one study38 
reported a significant improvement in the number of days 
per week with abdominal pain in patients taking citalopram 
compared with those taking placebo, and one36 reported that 
paroxetine produced a significant improvement in overall 
well-being compared with placebo. Limited information is 
available regarding tolerability, with dropout rates related as 
similar in two studies33,38 and overall adverse events described 
as comparable in three studies;33,35,37 one study reported no 
adverse event data.36 However, given the propensity of SSRIs 
to commonly cause GI adverse events of nausea, vomiting, 
and diarrhea, TCAs may have more utility in IBS-D than 
SSRIs appear to have.
Nonabsorbable antibiotics
With the growing body of evidence implicating a potential 
role of intestinal bacteria in IBS pathophysiology,39–42 the use 
of antibiotics to normalize gut flora has been investigated as 
a treatment for IBS. Several reports suggest a link between 
IBS and SIBO;20,21,43,44 however, the association remains 
controversial.45,46 The presence of SIBO may be associated 
with the IBS symptoms of gas, bloating, and altered bowel 
function through the fermentation of ingested lactulose or 
other carbohydrates by gut bacteria and stimulation of a 
gut immune response.20,21 Lactulose hydrogen breath test 
(LHBT) results have varied widely, with the presence of 
SIBO being diagnosed in 10%47 to 84%21 of IBS patients.   
A recent systematic review and meta-analysis of studies 
examining SIBO in IBS noted a pooled prevalence of 54% 
(95% CI 32%–76%) with a positive LHBT result.40 The use of 
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LHBT for determining SIBO has been controversial because 
of suboptimal specificity, leading to a high false-positive 
rate.40 However, other lines of evidence that implicate a 
role for altered bacteria in IBS   pathophysiology include the 
strong temporal association between acute enteric infec-
tion and subsequent IBS symptoms,39,48 qualitative changes 
observed in the intestinal microbiota of IBS patients,41,49 
evidence of low-grade inflammation in IBS patients (perhaps 
triggered by luminal bacteria50), and accumulating evidence 
of a therapeutic benefit of antibiotics and probiotics in 
IBS.44,51,52
Neomycin
Pimentel et al21 investigated the effect of a 10-day course 
of neomycin or placebo on IBS symptoms in 111 patients 
meeting Rome I criteria for IBS. IBS-D was present in 41% 
of patients at baseline, while 34% of patients had IBS-C. 
The   primary outcome was a composite symptom score 
that included scores for abdominal pain, diarrhea, and 
  constipation. In the intention-to-treat analysis, n eomycin 
achieved a greater reduction in the composite score than 
  placebo (35.0% ± 5.0% vs 11.4% ± 9.3% reduction, 
  respectively; P , 0.05); the   reduction was also significant 
for neomycin in the   subgroup of patients with abnormal 
baseline LHBT results (P , 0.01).21 Further, more patients 
treated with neomycin than with placebo achieved a $ 50% 
reduction in composite score (43% vs 23%, respectively; 
P , 0.05). Among the 41 neomycin-treated patients who 
had an abnormal LHBT finding at baseline, eight (20%) had 
a normal LHBT result after treatment; this group experi-
enced a greater improvement in symptoms than those whose 
LHBT result remained abnormal. Adverse events during 
the study were not adequately detailed to compare the two   
groups.21
Rifaximin
Rifaximin, a nonabsorbable antibiotic with activity against 
gram-negative and gram-positive bacteria, as well as aerobic 
and anaerobic bacteria,53 is the most extensively studied 
medication in its class for IBS (Table 3).21,44,51,54–58 Stud-
ies published to date have randomized patients who met 
Rome I,44 Rome II,54–60 or a combination of Rome II IBS 
criteria and presentation with intestinal gas-related symp-
toms (bloating or excessive flatulence).51 One study limited 
enrollment to patients with IBS-D,54–57 while the largest two 
trials evaluated patients with nonconstipated IBS.59,60 Overall, 
patients were to receive rifaximin or placebo for 10–14 days 
and be followed for 10–12 weeks thereafter.
Pimentel et al44 treated 87 patients with either rifaximin 
400 mg three times daily or placebo for 10 days with sub-
sequent follow-up for 10 weeks. Results showed significant 
improvements in global symptoms of IBS (P = 0.02 vs 
placebo) and bloating (P = 0.01 vs placebo) throughout 
the 10-week follow-up, although differences in relief of 
  abdominal pain, diarrhea, and constipation between the two 
groups were not significant.
In a more recent, larger phase II study (N = 388) reported 
only in abstracts to date,54–57 rifaximin 550 mg twice daily or 
placebo was administered for 14 days to adults with IBS-D, 
defined by Rome II criteria, who were followed for 12 weeks. 
The rifaximin treatment group had a significantly higher 
percentage of patients than the placebo group with sustained 
global symptom improvement (52% vs 44%, respectively; 
P = 0.03) and bloating (46% vs 40%; P = 0.04) throughout 
the 12 weeks.54 These improvements were more evident 
in patients with mild to moderate symptoms at baseline55 
and, notably, rifaximin did not significantly improve global 
IBS symptoms or bloating versus placebo in patients with 
severe IBS symptoms.56 At 4 weeks, rifaximin significantly 
improved overall quality of life from baseline (P = 0.02);57 
improvements in the individual domains of dysphoria, 
body image, health worry, social reaction, and relationship 
improvements were significant (P , 0.05 for each) compared 
with placebo. Quality of life measures at the trial endpoint 
were not reported.57
Most recently, Pimentel et al22 reported results from 
two identically designed, multicenter, phase III, placebo-
controlled trials (TARGET 1 N = 623; TARGET 2 
N = 637; total N = 1260) in patients with nonconstipated 
IBS (defined by Rome II criteria) who were treated with 
rifaximin 550 mg or placebo three times daily for 2 weeks 
and followed for an additional 10 weeks. Adequate relief 
of global IBS symptoms for at least 2 weeks of the first 4 
weeks after treatment (the primary endpoint) was signifi-
cant for rifaximin compared with placebo in both studies 
(TARGET 1 40.8% vs 31.2%, respectively, P = 0.01; TAR-
GET 2 40.6% vs 32.2%, respectively, P = 0.03). Likewise, 
rifaximin treatment yielded a significantly greater rate of 
adequate relief of IBS-associated bloating over this same 
time period compared with placebo (TARGET 1 39.5% vs 
28.7%, P = 0.005; TARGET 2 41.0% vs 31.9%, P = 0.02). 
Global symptom relief was also observed in both trials 
during follow-up, with the exception of relief of bloating 
in TARGET 1, where differences were significant between 
rifaximin- and placebo-treated patients for only the first   
2 months.22
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Overall, the safety profile of rifaximin appears similar 
to that of placebo.22,44 However, given the high prevalence 
of IBS in the general population, the chronic and recurrent 
nature of the disorder, and the potential for repeated use of 
antibiotics to treat this condition, induction of antibiotic 
resistance has been raised as a clinical issue that warrants 
further examination.61,62 Indeed, the new drug application for 
rifaximin submitted to the FDA for the indication of noncon-
stipated IBS was recently addressed in a complete response 
letter and was not approved with the data submitted; the FDA 
has requested additional data on retreatment with rifaximin 
in view of the hypothetical risk of antibiotic resistance with 
repeated courses.63
Alosetron
Alosetron is a selective 5-HT3 antagonist that is currently the 
only FDA-approved agent for IBS-D, specifically in women 
with severe IBS-D who have an inadequate response to con-
ventional therapy.26 The efficacy of this medication in IBS 
is thought to result from selective antagonism of the 5-HT3 
receptor, leading to normalization of several key abnor-
malities implicated in the pathophysiology of IBS-D: GI 
motility, intestinal secretion, and pain perception or visceral 
hypersensitivity.9,10,18,19 Alosetron affects motor activity by 
slowing intestinal tract transit time24,64 and enhancing fluid 
reabsorption. Alosetron reduces sensation of IBS-related 
visceral pain by decreasing blood flow to the brain’s emo-
tional motor center23 by relaxing colonic tissue and altering 
the perception of distention in the abdomen.65
Numerous randomized controlled trials investigated 
the effect of alosetron on IBS (Table 4).66–75 Each of these 
studies enrolled at least 300 patients with IBS, with most 
enrolling more than 600 patients. Women made up approxi-
mately 84% of the overall clinical trial population.66–78 
The diagnosis of IBS in these investigations was based on 
Rome I66–69,71,72,74,76 or Rome II70,73,75,77,78 criteria. Three of the 
more recent studies included women with nonconstipated 
IBS, IBS-D, or severe IBS-D,73,75,77,78 reflecting patient popu-
lations that are more consistent with the use of alosetron in 
the clinical practice setting.79
Review of the clinical data shows that alosetron has 
consistently demonstrated efficacy in producing significant 
relief of abdominal pain and discomfort compared with 
placebo.66–69,74,76,77 Camilleri et al66 found that alosetron 1 mg 
and 2 mg twice daily provided adequate relief of pain and dis-
comfort in female patients with IBS significantly more often 
than placebo (P , 0.05).66 Likewise, Bardhan et al67 found 
that alosetron 2 mg twice daily significantly increased the pro-
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specifically in women (P # 0.05). A later dose-ranging trial 
performed in men with IBS-D revealed that alosetron 1 mg 
twice daily provided significantly more relief from IBS pain 
than placebo (P = 0.012), whereas no significant effect was 
seen with the dosages of 0.5 mg, 2 mg, or 4 mg twice daily.76 
The most consistent and statistically significant effect of alos-
etron was on adequate relief of abdominal pain68,69,74,76,77 when 
given at a dosage of 1 mg twice daily. This significant abdomi-
nal pain relief was observed in clinical trials typically of 12 
weeks’ duration, but benefits have also been   demonstrated 
over the long term. Chey et al74 found that patients receiving 
alosetron had significantly greater 48-week average adequate 
relief of pain than patients receiving placebo.
Alosetron has been shown to improve multiple other 
IBS symptom domains, and significant global symptom 
improvements on the Global Improvement Scale or by 
overall satisfaction ratings (P , 0.05 for all)70,73,75,77 have 
been noted. Additionally, significant improvements in stool 
frequency66–70,74,75,77 and stool consistency66–70,74–77 were 
reported in several studies (P , 0.05 for all). One of the most 
bothersome IBS symptoms, fecal urgency, has been shown to 
be significantly improved with alosetron.66,68–70,74,75,77 In par-
ticular, when patients with severe bowel urgency symptoms 
(defined as lack of satisfactory control of urgency for at least 
10 of 14 days during the trial screening phase) were assessed 
over 12 weeks of treatment, alosetron elicited significant 
improvement of urgency, as evidenced by the proportion 
of patients who achieved satisfactory control of urgency 
for a median 66% of days, compared with a median 43% of 
days in those receiving placebo (P , 0.001).75 Moreover, 
alosetron has been shown to improve the quality of life of 
IBS patients.71 Watson et al71 reported statistically significant 
improvements from baseline in IBS-D in all nine domains 
of the IBS Quality of Life Questionnaire (emotional health, 
mental health, sleep, energy, physical functioning, food/
diet, social functioning, role-physical, and sexual relations) 
compared with placebo in one study (n = 626; P # 0.05 for all 
nine) and in eight of nine domains in another study (n = 647; 
P # 0.05 for all eight).
Alosetron was generally well tolerated in clinical 
t  rials; however, it was associated with a greater incidence 
of constipation than placebo, which appeared to be dose 
related.66–70,72,74–77 Ischemic colitis (IC) and complications of 
constipation are known serious adverse events that have been 
associated with alosetron in clinical trials and p  ostmarketing 
experience.76,77,80,81 In IBS clinical trials, the cumulative inci-
dence of IC in women receiving alosetron was 0.2% through 
3 months and 0.3% through 6 months. The incidence of seri-
ous complications of constipation was approximately 0.1% in 
women who were treated with either alosetron or placebo.26 A 
recent review of alosetron postmarketing safety data gathered 
over the past 5–6 years has shown that the incidence of IC and 
complications of constipation has been stable over time, and 
occurrences have remained rare since its reintroduction to the 
market in 2002 (0.36 and 0.95 cases per 1000 patient-years, 
respectively).81 Moreover, serious outcomes of these adverse 
events have been mitigated effectively with the alosetron pre-
scribing program, with no cases of transfusions, surgeries, or 
deaths reported since the institution of the risk management 
program (now a Risk Evaluation and Mitigation Strategies 
[REMS] program).81
Despite several hypotheses that have been proposed to 
explain the association of alosetron and other serotonergic 
drugs with IC, the underlying pathophysiologic mechanism 
or mechanisms by which IC develops remain unknown. It is 
interesting to note that numerous epidemiologic studies using 
various methodologies have described an increased risk for 
the development of IC in patients with IBS.82–87 Across these 
studies, a diagnosis of IBS was associated with a 2–3.4 times 
increase in the odds of developing IC, bringing into question 
whether IC is part of the natural history of IBS.88
The ACG IBS Task Force classified the quality of evi-
dence supporting the use of alosetron in IBS as high and 
has determined that alosetron is more effective than placebo 
at relieving global IBS symptoms in men and women with 
IBS-D.3 Given the risk of potentially serious side effects of 
IC and complications of constipation, the benefit:risk ratio for 
alosetron is most favorable in women who have not responded 
to conventional therapies, and indeed this is the population 
for which alosetron is indicated.
Discussion
Evidence for the use of the TCAs, antibiotics, and the 5-HT3 
antagonist alosetron in patients with IBS and IBS-D indicates 
that these agents are effective for the treatment of multiple 
symptoms operant in the IBS patient. The 2009 ACG IBS 
Task Force has recognized these options as the treatment 
strategies with the strongest evidence supporting their use 
in this population.3 Rather than being one-dimensional treat-
ments, each of the highlighted classes or agents described 
has the potential to modulate an underlying pathophysiologic 
mechanism believed to cause IBS, in contrast to conventional 
agents that are often prescribed but not FDA approved spe-
cifically for IBS-D.
The TCAs are thought to act on visceral hypersensitiv-
ity by increasing pain thresholds and may act peripherally 
as well to slow gut transit times.3,27 TCA studies in IBS are 
few in number and include small patient populations, but 
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amitriptyline28,29 and desipramine30,31 appear to be effective 
for global IBS symptom relief. The capacity of these agents 
to reduce abdominal pain is less clear. The largest study 
of any of the TCAs is an investigation of desipramine.31 
However, in this study, interpretation of the efficacy of 
desipramine was compromised by high patient withdraw-
als and noncompliance, although results showed it was 
effective in those patients who were able to tolerate it. The 
other TCA reviewed here, imipramine 25–50 mg/day, did 
not show efficacy in IBS but was evaluated in only two 
small-scale studies.32,33 This agent may be effective in larger 
patient populations and perhaps at higher doses. Overall, 
the reported efficacy of the TCAs in the control of stool 
frequency and consistency has varied.28–30 The tolerability of 
the TCAs depends largely on the propensity of these agents 
to exert cholinergic, histaminergic, and adrenergic side 
effects,16 which indeed may affect adherence. Additionally, 
the prescriber must also be cognizant that the TCAs can be 
associated with death in overdose,34 especially in light of 
suicidal ideation findings that were related purely to IBS 
symptoms in secondary and tertiary care patients observed 
by Miller et al.34
Evidence that antibiotics show a therapeutic benefit in 
IBS has been evaluated and scrutinized for many years; 
however, the role of antibiotics in the management of IBS 
remains undefined, owing in part to uncertainty about 
the association between altered intestinal flora and IBS 
pathogenesis. Study findings suggesting differences in 
the gut microbiota between IBS sufferers and healthy 
controls41,49 have been inconsistent, and the relative con-
tributions of the various altered bacterial populations to 
IBS physiology and symptom development have not been 
determined.89 Likewise, the link between SIBO and IBS 
symptoms remains controversial, particularly because of 
the wide variability in reported prevalence rates of SIBO 
in IBS patients (most studies report a 10% prevalence, 
whereas Pimentel et al21 have a reported prevalence as 
high as 84%), and the lack of sensitivity and specificity 
of breath testing methods (ie, lactulose, glucose, sucrose) 
for diagnosing SIBO.40,45,90,91 Indeed, in the single study 
that used direct aspiration and culture of jejunal secretions 
to assess SIBO, no difference in the prevalence of SIBO 
(defined as $105 cfu/mL) was found between IBS patients 
and controls.92 Additionally, a retrospective cohort study 
by Chan et al93 found that only 32% of those receiving 
an antibiotic course for SIBO   realized a complete symp-
tomatic response. Interestingly, the IBS condition was 
found to be an independent risk factor for an incomplete 
response to antibiotics using multivariate regression 
analysis. Most recently, Yu et al45 found that the abnormal 
rise in H2 measured by the LHBT appears to be explained 
by variations in orocecal transit time in patients with IBS 
and not by the presence of SIBO.
Acute clinical trials of rifaximin in nonconstipated IBS 
have provided evidence of global symptom improvements and 
bloating relief.44,51,54–60 At present, it is not clear if r  ifaximin 
can provide durable effects beyond 3 months, if it provides relief 
in patients with severe symptoms, or if repetitive t  reatment 
would lead to antibiotic resistance.   Longer-term studies of 
rifaximin are necessary to support its use in IBS.
Alosetron is the only FDA-approved agent for use in women 
with severe IBS-D. Its proposed mechanism of action involves 
targeting the 5-HT3 serotonin receptor subtype known to play 
a role in influencing GI motility, intestinal secretion, and 
pain perception or visceral hypersensitivity.9,10,18,19   Alosetron 
is effective for relieving global IBS symptoms70,73,75,77 and 
abdominal pain/discomfort,66–69,74,76,77 as well as multiple other 
symptom domains, including stool frequency,66–70,74,75,77 stool 
consistency,66–70,74–77 and fecal urgency,66,68–70,74,75,77 for up to 
1 year of treatment. Likewise, alosetron improves quality 
of life in IBS patients.71,78 Institution of the REMS program 
upon the market reintroduction of alosetron has provided 
health care providers and patients with a valuable tool allow-
ing proper patient selection. The potential for side effects 
of constipation and IC are predictable and well understood 
such that complications from either of these adverse events 
have been mitigated to the point of being virtually nonex-
istent since the REMS program was initiated.81 Alosetron 
represents a viable and highly effective therapeutic option in 
women with severe IBS-D, providing multisymptom relief, 
a well-characterized tolerability profile, and improvements 
in quality of life.
Conclusion
High-quality placebo-controlled clinical evidence of effi-
cacy in IBS is available for TCAs, antibiotics, and alosetron. 
Depending on the nature of the symptoms in the individual 
patient with IBS, each of these targeted therapies is able 
to provide benefit that goes beyond the monosymptomatic 
relief conferred by conventional therapies. Knowledge of 
the differential treatment effects of each of these agents may 
facilitate development of a more personalized treatment 
approach in IBS. Despite current and emerging evidence, 
alosetron remains the only therapeutic option that is FDA 
approved for the treatment of IBS-D. As new therapies are 
investigated, the effects of specific agents on multitiered 
patient-reported outcome measures (as are now recom-
mended by the FDA)94 will be informative to the field and 
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will help shape future evidence-based practice guidelines 
for the treatment of IBS.
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